Also, a liposomal formulation of TRAIL showed improved serum pharmacokinetics, enabling bortezomib to sensitize tumor cells to TRAIL induced apoptosis in a soluble TRAIL resistant neuroblastoma model [51]. The gene discussed is TNFSF10; the disease is neuroblastoma.